FOR IMMEDIATE RELEASE

Artemis Therapeutics Announces $1 Million AI Technology Licensing Agreement with Rakovina Therapeutics

Exclusive worldwide licence for DNA-damage response oncology drug discovery provides commercial validation of Artemis.AI™ platform and establishes framework for potential therapeutic co-development

Vancouver, BC — Nov. 10, 2026 — Artemis Therapeutics Inc. ("Artemis" or the "Company"), a privately held drug discovery and development company advancing artificial intelligence-driven molecular discovery, today announced that it has entered into a definitive software licensing agreement with Rakovina Therapeutics Inc. (TSX-V: RKV) (FSE: 7JO0) (OTCMKTS: RKVTF), a biopharmaceutical company focused on developing innovative cancer therapies.

Under the agreement, Rakovina has secured an exclusive, worldwide licence to use Artemis.AI™, the Company's advanced artificial intelligence, computational chemistry and machine-learning platform, within a defined field of DNA-damage response (DDR) oncology drug discovery and development.

The agreement provides Artemis with $1 million in share-based consideration and establishes a framework through which the companies may pursue the co-development of selected therapeutic candidates identified using the Artemis.AI™ platform.

Frank Holler, Executive Chairman & CEO of Artemis Therapeutics, commented:

"Securing this licensing agreement with Rakovina represents an important commercial milestone for Artemis and demonstrates the potential of our technology platform to create value through strategic industry partnerships. Our objective is to build a differentiated drug discovery company that can generate value through both internally developed therapeutic assets and carefully selected licensing opportunities. This agreement allows us to leverage

the capabilities of Artemis.AI™ in a highly relevant area of oncology while preserving the opportunity to participate in the future development of promising therapeutic candidates."

Advancing AI-Driven Oncology Drug Discovery

The Artemis.AI™ platform builds on more than two decades of research in computational chemistry, molecular modelling and AI-enabled drug discovery led by Artemis co-founders Dr. Artem Cherkasov and Dr. Mads Daugaard and collaborators at the University of British Columbia. The underlying technology integrates advanced machine learning, computational chemistry and large-scale virtual screening to accelerate the identification and optimization of potential therapeutic compounds.

Dr. Cherkasov's research team developed Deep Docking™, an AI-enabled computational approach capable of exploring vast chemical libraries at speeds and scales previously unattainable using conventional screening methods. The technology has demonstrated its capabilities by screening more than 40 billion molecules and achieving first-place results in two international CACHE Challenges focused on computational drug discovery.

The application of Artemis.AI™ to DNA-damage response oncology represents an opportunity to combine advanced computational discovery with Rakovina's expertise in cancer biology and therapeutic development.

Dr. Artem Cherkasov, Co-Founder & President of Artemis Therapeutics, commented:

"The ability to explore enormous chemical spaces efficiently and systematically is fundamentally changing how we approach drug discovery. Artemis.AI™ brings together advances in artificial intelligence, molecular modelling and computational chemistry to identify promising compounds that may be difficult to discover using traditional approaches. DNA-damage response pathways represent a particularly compelling area for applying these capabilities, and we look forward to seeing how the combination of our computational technology and Rakovina's oncology expertise can accelerate the discovery and optimization of new therapeutic candidates."

Licensing Agreement and Potential Co-Development Opportunities

Under the terms of the agreement, Rakovina will issue common shares to Artemis with an aggregate value of $1 million, payable in two tranches of $500,000 each. The first tranche will be issued following the effective date of the agreement and acceptance by the TSX

Venture Exchange. The second tranche will be issued on the later of the first anniversary of the effective date and the required exchange approval. The number of shares issued will be determined according to the pricing provisions of the agreement and applicable securities requirements.

Rakovina will retain ownership of compounds, data and results generated through its research activities within the licensed field, subject to the terms of the agreement and Artemis' underlying platform intellectual property rights. Importantly, the agreement also provides Artemis with an option to participate in the co-development of selected drug candidates identified through the collaboration.

If Rakovina designates a compound as a development-track candidate, Artemis will have 60 days following receipt of the required information to exercise its option to negotiate a candidate-specific co-development agreement. Any such arrangement would be negotiated separately and would address the allocation of development costs, risks and potential commercial returns based on the respective contributions of the two companies.

The agreement does not itself establish a co-development arrangement for any specific compound, and future development activities will depend on scientific results, validation and subsequent agreements.

Supporting Artemis' Asset-Driven Growth Strategy

The licensing agreement represents an important step in Artemis' strategy to establish its AI-driven discovery platform as a foundation for both proprietary therapeutic development and selected commercial partnerships. Unlike traditional AI drug discovery service providers, Artemis is focused on identifying, validating and advancing promising therapeutic candidates while retaining opportunities to participate in the long-term value created through its discoveries.

The agreement with Rakovina demonstrates how Artemis.AI™ can be applied within a defined therapeutic field while maintaining the Company's ability to advance independent research and development programs and pursue additional opportunities outside the licensed field. By combining computational innovation with biological expertise and a flexible commercial strategy, Artemis aims to accelerate therapeutic discovery while building a portfolio of opportunities for future development, partnerships and licensing.

The licence became effective October 15, 2026, subject to its terms and the TSX Venture Exchange acceptance required for the share issuance.

About Artemis Therapeutics

Artemis Therapeutics Inc. is a privately held drug discovery and development company developing advanced artificial intelligence technologies to accelerate the identification and development of novel therapeutics. Built on more than two decades of research at the University of British Columbia, the Company's Artemis.AI™ platform integrates computational chemistry, structural biology and machine learning to enable the exploration of complex chemical and biological systems at scale.

Artemis combines advanced computational discovery with biological validation and an asset-driven development strategy focused on advancing promising therapeutic candidates and creating long-term value through proprietary programs and strategic partnerships.

For more information, visit www.artemistherapeutics.ai.

About Rakovina Therapeutics

Rakovina Therapeutics Inc. is a biopharmaceutical research company focused on the development of innovative cancer treatments. The Company's research targets DNA-damage response pathways using artificial intelligence-enabled approaches to identify and optimize promising therapeutic candidates.

Rakovina is advancing a pipeline of DNA-damage response inhibitors with the goal of progressing selected candidates toward clinical development in collaboration with pharmaceutical partners.

For more information, visit www.rakovinatherapeutics.com.

Contact

Vanessa Ooms, *Marketing & Communications Director*

ARTEMIS THERAPEUTICS INC.

vooms@artemistherapeutics.ai